on behalf of the MEPAFAR study workgroup Masked uncontrolled hypertension (MUCH) is associated with an increased cardiovascular risk. This condition is frequent in the community pharmacy (i.e., CP-MUCH), but there is no evidence on the factors associated with its presence in that setting. The aim of this analysis was to explore these factors. A sample of 98 treated hypertensive patients from the MEPAFAR study, with normal community pharmacy blood pressure (CPBP < 135/85 mmHg), were analyzed. Blood pressure (BP) was also measured at home (4 days) and monitored for 24 h. CP-MUCH was identified when either ambulatory (daytime) or home BP averages were equal to or higher than 135/85 mmHg. A multivariate logistic regression analysis was carried out to identify the factors associated with CP-MUCH. The prevalence of CP-MUCH tends to be higher as systolic and diastolic CPBP increase, reaching 47% in patients with both systolic and diastolic CPBP equal to or higher than 123 mmHg and 79 mmHg, respectively. The multivariate regression analysis showed only systolic CPBP as an independent factor of CP-MUCH [ ≥ 123 mmHg: odds ratio = 16.46 (P = 0.012); from 115 to 122.9 mmHg: odds ratio = 10.74 (P = 0.036); systolic CPBP < 115 mmHg as the reference]. Further assessment, using ambulatory and/or home BP monitoring, is recommended in patients with normal CPBP, but systolic CPBP equal to or higher than 115 mmHg. A more feasible approach would be evaluating patients with systolic CPBP equal to or higher than 123 mmHg and diastolic CPBP equal to or higher than 79 mmHg.
Introduction
Masked uncontrolled hypertension (MUCH) is defined in those treated hypertensive patients who have elevated ambulatory (ABP) or home blood pressure (HBP) despite normal physician office measurements [1] . This condition is found in 22% of treated patients and has been associated with an increased cardiovascular risk [2] . This higher risk may be explained by the fact that ABP and HBP have been shown to be stronger predictors of target organ damage and cardiovascular events than blood pressure (BP) measured in a physician's office [3, 4] .
MUCH could remain undetected if only office BP readings are available for evaluation. As a consequence, if normal BP figures are measured in the physician's office, the necessary adjustments in treatment may not be made and the underlying risk associated with elevated ABP or HBP would therefore not be well managed. As measurement of out-of-office BP in all normotensive individuals is not a feasible or an efficient strategy in daily clinical practice, several studies have been carried out to identify the factors associated with the presence of MUCH [5] [6] [7] [8] [9] . By considering these factors and identifying patients who are more likely to have MUCH, a further assessment, using ABP or HBP monitoring (ABPM or HPBM), could be recommended.
MUCH has also been identified as a relatively frequent condition in the community pharmacy (i.e., CP-MUCH) [10, 11] . Particularly in this case, if normal BP figures are measured in the community pharmacy, pharmacists would not refer patients to a physician, and again, the necessary changes in treatment would not be made. Given that CP-MUCH could influence both decisionmaking processes and health outcomes, the presence of this condition should be investigated carefully when pharmacists deliver pharmaceutical care services to treated hypertensive patients.
To our knowledge, there are no reports in the literature on the factors associated with CP-MUCH. As a consequence, community pharmacists do not have guidelines that would allow them to better identify patients who are likely to present with CP-MUCH. In light of the prevalence of CP-MUCH and given its clinical implications, a subgroup analysis of patients with normal community pharmacy BP (CPBP) who were included in the MEPAFAR study [11] was carried out to explore the factors associated with CP-MUCH.
Methods
The MEdida de la Presión Arterial en FARmacia (MEPAFAR) study was a cross-sectional study carried out from June 2008 to June 2009 in eight Spanish community pharmacies. The main aim of the study was to assess the agreement between CPBP, daytime ABP, and HBP in treated hypertensive patients [11] , and thus the capacity of the CPBP measurement method to evaluate the effectiveness of antihypertensive treatment. The protocol of the MEPAFAR study was assessed and approved by the Research Ethics Committee of the University of Granada (Spain). BP measurement methods have been described comprehensively in previous publications [11, 12] . Briefly, CPBP was measured at four visits, by the same pharmacist at each pharmacy, over a 4-week period. At each visit, three BP measurements were taken (2-3 min apart) on the control arm (arm on which CPBP was higher on the first visit). Patients' visits to the pharmacy were scheduled at the same time for all four time points ( 1 h). The mean CPBP was calculated discarding the data from the first visit and the first measurement from each visit.
For the purpose of this subanalysis, normal CPBP was defined by systolic BP (SBP) less than 135 mmHg and diastolic BP (DBP) less than 85 mmHg.
At home, patients monitored their BP over 4 consecutive working days, taking three measurements in the morning (2 min apart, 6 a.m. to 9 a.m.) and three measurements in the evening (6 p.m. to 9 p.m.) on the nondominant arm. HBP readings were stored in the device's memory. The mean HBP was calculated discarding values obtained on the first day and using the first and second measure from each morning and each evening. Normal HBP was defined by SBP less than 135 mmHg and DBP less than 85 mmHg. The clinically validated OMRON M10-IT automatic electronic device (Omron Corp., Tokyo, Japan) [13] was used both at home and in the community pharmacy.
ABPM was performed on a working day (24 h) using the nondominant arm. Measurements were taken every 20 min (7 a.m. to 10 p.m.) or 30 min (10 p.m. to 7 a.m.). The clinically validated Spacelabs Medical 90207-5Q monitor (Spacelabs Inc., Redmond, Washington, USA) was used [14] . The average daytime ABP was calculated according to a sleep diary kept by each patient. Normal daytime ABP was defined by SBP less than 135 mmHg and DBP less than 85 mmHg.
On the basis of recently acknowledged definitions [15, 16] , CP-MUCH was defined when an average CPBP (SBP/DBP) of less than 135/85 mmHg was combined with one or both of the following: average daytime ABP equal to or higher than 135/85 mmHg and/or average HBP equal to or higher than 135/85 mmHg.
To characterize the study sample, the following variables were collected: age, sex, smoking status, BMI, number of antihypertensive drugs used, adherence to antihypertensive drugs (Morisky-Green test [17] ), history of previous cardiovascular disease (stroke, myocardial infarction, angina, or peripheral artery disease), and presence of diabetes or dyslipidemia (documented diagnosis or previously prescribed drug treatment).
Statistical analysis
SPSS, version 15.0 (SPSS Inc., Chicago, Illinois, USA) was used for the statistical calculations. Mean and SD were used to summarize quantitative variables. Qualitative variables were described using frequencies and percentages. To compare the quantitative variables, Student's t-test for independent samples was used.
Differences between CPBP, HBP, and daytime ABP were assessed by repeated-measures analysis of variance applying the Bonferroni correction. χ 2 and Fisher's exact tests were used for comparisons of proportions.
To identify the independent factors associated with CP-MUCH, a multivariate logistic regression analysis was used. As candidate independent variables for the multivariate models, CPBP (SBP and DBP) and all the variables collected to characterize the study sample were considered. Univariate logistic regression was used to select the independent variables that were finally entered in the multivariate models (P < 0.2). A-priori, quantitative independent variables (i.e. SBP, DBP, age, and BMI) were entered into the model in their original form. However, none of them showed a linear relationship with the dependent variable when linearity was checked. Thus, these quantitative variables were converted into categorical variables on the basis of their tertiles (i.e. each variable was stratified into three groups with similar numbers of individuals). A second multivariate logistic model was constructed using CP-MUCH, defined by daytime ABP only, as the dependent variable.
The goodness-of-fit of the models was assessed using the Hosmer-Lemeshow test (the model was considered acceptable if the test was not statistically significant). A P-value less than 0.05 was considered statistically significant.
Results
The presented the highest SBP figures [128.6 (SD: 6.6) at the pharmacy, 140.0 (SD: 6.4) mmHg at home, and 139.6 (SD: 3.4) mmHg by ambulatory monitoring] (Fig. 1 ). Table 2 and Fig. 2 , the proportion of individuals with CP-MUCH tends to be higher as systolic and diastolic CPBP increases; for example, the prevalence of CP-MUCH reached 47% (seven out of 15) in patients with both systolic and diastolic CPBP equal to or higher than 123 mmHg and 79 mmHg, respectively. On the basis of the univariate regression analysis, age, diabetes, and both systolic and diastolic CPBP were selected as factors to be entered into the multivariate model ( Table 2 ). The multivariate regression analysis indicated systolic CPBP equal to or higher than 115 mmHg as an independent factor of CP-MUCH [from 115 to 122.9 mmHg: odds ratio (OR) = 10.74 (P = 0.036); ≥ 123 mmHg: OR = 16.46 (P = 0.012); systolic CPBP < 115 mmHg as the reference]. When only daytime ABP was used to identify CP-MUCH (n = 13), again, only systolic CPBP was found to be associated [ ≥ 123 mmHg: OR = 10.85 (P = 0.036); systolic CPBP < 115 mmHg as the reference].
As shown in

Discussion
Measurement of BP in community pharmacies is a widespread practice that is recommended by several hypertension societies [18] [19] [20] . Nevertheless, some caution should be exercised when considering and using this method; specifically, when normal figures are obtained, CPBP readings might encourage erroneous conclusions about hypertension control in some cases [10, 11] . In fact, in this study, CP-MUCH was identified in a quarter of the patients with normal CPBP. Ideally, ABPM and/or HBPM would be recommended in all patients with normal CPBP; however, this is not feasible or achievable in practice. In light of this, our results might help community pharmacists identify individuals who are more likely to present CP-MUCH and, thus, prioritize the use of the out-of-pharmacy BP methods among treated hypertensive patients with normal CPBP.
On the basis of the results of the multivariate analysis, CP-MUCH was associated with systolic CPBP and should be investigated when systolic figures equal to or higher than 115 mmHg are obtained. However, because of the low BP cut-off point, this recommendation still encourages a wide use of ABPM and/or HBPM that might not be achievable in some cases (for example, a patient's lack of willingness to monitor BP). Additional results of this study allow identification of certain circumstances in which either the prevalence of CP-MUCH or the relevance of the situation might be greater. When CP-MUCH was defined by means of ABPM only, the multivariate analysis showed that individuals with systolic CPBP equal to or higher than 123 mmHg are more likely to present CP-MUCH. This is particularly noteworthy when it is considered that ABPM is the reference method in the management of hypertension. In addition, although diastolic CPBP was not associated with CP-MUCH, the prevalence of CP-MUCH increased (across any SBP strata) as diastolic CPBP was closer to the uppernormal limits (≥79 mmHg; Fig. 2 ). Overall, HBP and ABP figures were not remarkably increased in patients with CP-MUCH (Table 1 and Fig. 1 ). Only individuals with both home and daytime uncontrolled BP showed high SBP figures. Interestingly, four out of these five individuals had systolic CPBP equal to or higher than 123 mmHg. On the basis of these observations taken together, community pharmacists would be encouraged to further assess BP control (using ABPM and/or HBPM) when systolic CPBP is equal to or higher than 123 mmHg and diastolic CPBP is equal to or higher than 79 mmHg. From a practical perspective, this might represent a more feasible approach than considering all the individuals with systolic CPBP equal to or higher than 115 mmHg.
This study provides original evidence of the factors associated with CP-MUCH, which, at first instance, should not be assumed to be the same condition as present in the physician office. This statement is based on the results of the Palmera study [10] , in which CPBP and physician office BP inversely classified BP control in 34.3% of patients (κ coefficient for the agreement between methods: 0.35). These results suggest that individuals with CP-MUCH would be unlikely to be the same individuals as those presenting with MUCH in the physician office. Thus, the factors associated with MUCH should be studied independently in both of these settings. As a reasonable starting point, our primary analysis included and checked many factors that have been associated previously with MUCH in the physician office: sex [5] [6] [7] , age [5] [6] [7] , smoking status [6] , clinic BP [5] [6] [7] [8] [9] (instead of CPBP), BMI [5, 8] , number of antihypertensive drugs taken [8, 9] , and diabetes [5] . In our opinion, other potential factors [21] might be taken into account in the future, also considering undiagnosed patients and large samples. Another interesting subject to be addressed by future research would be the reproducibility of CP-MUCH. Nonetheless, although additional evidence is generated in other studies, we believe that our results will be useful toward improving the assessment of BP in treated hypertensive patients and for detecting CP-MUCH.
According to recent hypertension guidelines [15, 16] , we used a single definition of CP-MUCH, combining the results of both HBPM and ABPM. On the one hand, this represents a more conservative approach, as, theoretically, patients with either elevated HBP or elevated daytime ABP require further evaluation. On the other, most patients with CP-MUCH had only one out-ofpharmacy BP elevation, thus indicating that both methods are complementary and that incomplete information is obtained when one is used in isolation. It should be noted that all patients included in this analysis were adherent to the HBPM protocol (4 days; three measurements in the morning and three in the evening); thus, the minimum number of HBP measures established by international guidelines for assessing hypertension was reached [22, 23] .
The results of this study are constrained by the procedures used for measuring BP at the community pharmacy. The measurement approach is supported by the Spanish Society of Hypertension [19] and was initially established on the basis of guidelines for BP measurement in the clinic [24] , which recommend taking repeated BP measures per visit over at least two to three visits. In addition, on the basis of the previous results of this study [12, 25] , the data from the first pharmacy visit and the first measurement from each visit were discarded to minimize the white-coat effect. Thus, it seemed reasonable to use the same threshold limits for HBP and Prevalence of CP-MUCH across blood pressure strata in the community pharmacy. BP, blood pressure; CP-MUCH, community pharmacy masked uncontrolled hypertension. daytime ABP. This protocol for measuring CPBP follows the guidelines and thus meets the standards of quality care. Moreover, in our opinion, it is simple and might be easily implemented in practice. Finally, it should be noted that measurement of BP by community pharmacists can be used as a first step in assessing BP control in hypertensive treated patients who are not willing to monitor or capable of monitoring either HBP or ABP [26] . Then, on the basis of measured CPBP, the pharmacist may recommend a further BP assessment to some patients using ABPM and/or HBPM [19, 23, 27] .
In conclusion, CP-MUCH, which affected a quarter of the patients in this study, was only associated with systolic CPBP. Further assessment, using ABPM and/or HBPM, is recommended in treated hypertensive patients with controlled CPBP, but who have systolic figures equal to or higher than 115 mmHg. A more feasible approach, however, would be to evaluate patients with systolic and diastolic CPBP equal to or higher than 123 mmHg and 79 mmHg, respectively. These results may help promote better management of hypertension from the community pharmacy.
